Back to search resultsSummaryRMgm-1356
|
||||||||
*RMgm-1356| Successful modification | The parasite was generated by the genetic modification |
| The mutant contains the following genetic modification(s) | Gene tagging |
| Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 26565797 |
| MR4 number | |
| top of page | |
| Parent parasite used to introduce the genetic modification | |
| Rodent Malaria Parasite | P. berghei |
| Parent strain/line | P. berghei ANKA |
| Name parent line/clone | P. berghei ANKA 2.34 |
| Other information parent line | P. berghei ANKA 2.34 is a cloned, gametocyte producer line of the ANKA strain (PubMed: PMID: 15137943). |
| top of page | |
| The mutant parasite was generated by | |
| Name PI/Researcher | Roques M; Tewari R |
| Name Group/Department | School of Life Sciences, Queens Medical Centre |
| Name Institute | University of Nottingham |
| City | Nottingham |
| Country | UK |
| top of page | |
| Name of the mutant parasite | |
| RMgm number | RMgm-1356 |
| Principal name | CYC3-GFP |
| Alternative name | |
| Standardized name | |
| Is the mutant parasite cloned after genetic modification | Yes |
| top of page | |
| Phenotype | |
| Asexual blood stage | Live imaging of parasites revealed CYC3-GFP presence throughout the parasite cell body with a predominantly cytosolic localisation at most of the key Plasmodium life cycle stages examined (trophozoite, male and female gametocyte, zygote, ookinete, oocyst and salivary gland sporozoite). Deconvolution fluorescence imaging showed that CYC3-GFP was uniformly present throughout both the cytoplasm and the nucleus in trophozoites, gametocytes and ookinetes and noticeably enriched in the nucleus of ookinetes. |
| Gametocyte/Gamete | Live imaging of parasites revealed CYC3-GFP presence throughout the parasite cell body with a predominantly cytosolic localisation at most of the key Plasmodium life cycle stages examined (trophozoite, male and female gametocyte, zygote, ookinete, oocyst and salivary gland sporozoite). Deconvolution fluorescence imaging showed that CYC3-GFP was uniformly present throughout both the cytoplasm and the nucleus in trophozoites, gametocytes and ookinetes and noticeably enriched in the nucleus of ookinetes. |
| Fertilization and ookinete | Live imaging of parasites revealed CYC3-GFP presence throughout the parasite cell body with a predominantly cytosolic localisation at most of the key Plasmodium life cycle stages examined (trophozoite, male and female gametocyte, zygote, ookinete, oocyst and salivary gland sporozoite). Deconvolution fluorescence imaging showed that CYC3-GFP was uniformly present throughout both the cytoplasm and the nucleus in trophozoites, gametocytes and ookinetes and noticeably enriched in the nucleus of ookinetes. |
| Oocyst | Live imaging of parasites revealed CYC3-GFP presence throughout the parasite cell body with a predominantly cytosolic localisation at most of the key Plasmodium life cycle stages examined (trophozoite, male and female gametocyte, zygote, ookinete, oocyst and salivary gland sporozoite). Deconvolution fluorescence imaging showed that CYC3-GFP was uniformly present throughout both the cytoplasm and the nucleus in trophozoites, gametocytes and ookinetes and noticeably enriched in the nucleus of ookinetes. Fluorescent imaging showed no detectable CYC3-GFP expression in oocysts at 5 and 7 dpi. Expression of CYC3-GFP was first observed at low levels in the majority of oocysts at 10 dpi with the highest expression detected at 14 dpi. Oocysts that had formed fully mature sporozoites showed the highest protein expression. After 14 dpi, a decrease was observed in CYC3-GFP expression in oocysts up to day 21pi. |
| Sporozoite | Live imaging of parasites revealed CYC3-GFP presence throughout the parasite cell body with a predominantly cytosolic localisation at most of the key Plasmodium life cycle stages examined (trophozoite, male and female gametocyte, zygote, ookinete, oocyst and salivary gland sporozoite). Deconvolution fluorescence imaging showed that CYC3-GFP was uniformly present throughout both the cytoplasm and the nucleus in trophozoites, gametocytes and ookinetes and noticeably enriched in the nucleus of ookinetes. Fluorescent imaging showed no detectable CYC3-GFP expression in oocysts at 5 and 7 dpi. Expression of CYC3-GFP was first observed at low levels in the majority of oocysts at 10 dpi with the highest expression detected at 14 dpi. Oocysts that had formed fully mature sporozoites showed the highest protein expression. After 14 dpi, a decrease was observed in CYC3-GFP expression in oocysts up to day 21pi. |
| Liver stage | Not tested |
| Additional remarks phenotype | Mutant/mutation CYC3-GFP parasites were able to complete the full life cycle with no detectable phenotype observed from tagging with GFP including oocyst development at 14 days post infection (dpi) in mosquitoes. Live imaging of parasites revealed CYC3-GFP presence throughout the parasite cell body with a predominantly cytosolic localisation at most of the key Plasmodium life cycle stages examined (trophozoite, male and female gametocyte, zygote, ookinete, oocyst and salivary gland sporozoite). Deconvolution fluorescence imaging showed that CYC3-GFP was uniformly present throughout both the cytoplasm and the nucleus in trophozoites, gametocytes and ookinetes and noticeably enriched in the nucleus of ookinetes. Other mutants |
Tagged: Mutant parasite with a tagged gene| top of page | |||||||||||||||||||||||||||
| Details of the target gene | |||||||||||||||||||||||||||
| Gene Model of Rodent Parasite | PBANKA_1233200 | ||||||||||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_0518400 | ||||||||||||||||||||||||||
| Gene product | cyclin, putative | ||||||||||||||||||||||||||
| Gene product: Alternative name | P-Type Cyclin CYC3; CYC3 | ||||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||||||||||
| Name of the tag | GFP | ||||||||||||||||||||||||||
| Details of tagging | C-terminal | ||||||||||||||||||||||||||
| Additional remarks: tagging | |||||||||||||||||||||||||||
| Commercial source of tag-antibodies | |||||||||||||||||||||||||||
| Type of plasmid/construct | (Linear) plasmid single cross-over | ||||||||||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||||||||||
| Restriction sites to linearize plasmid | |||||||||||||||||||||||||||
| Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||||
| Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||||||||||
| Additional remarks genetic modification | |||||||||||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||||